Illumina Inc. (ILMN) News
Filter ILMN News Items
ILMN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ILMN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ILMN News From Around the Web
Below are the latest news stories about ILLUMINA INC that investors may wish to consider to help them evaluate ILMN as an investment opportunity.
Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6, 2025. |
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X SeriesIllumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits. |
Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applicationsIllumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits. |
Illumina price target lowered to $180 from $184 at Evercore ISIEvercore ISI analyst Vijay Kumar lowered the firm’s price target on Illumina (ILMN) to $180 from $184 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the |
Here’s Why Illumina, Inc. (ILMN) Is Among The Stocks Targeted By Activist Hedge FundsWe recently compiled a list of the 15 Stocks Targeted By Activist Hedge Funds. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other stocks targeted by activist hedge funds. Shareholder activism continued at a record pace in 2024 as activist hedge funds pushed for strategic changes […] |
EU Approves Nvidia’s Run:ai TakeoverNvidia’s takeover of Israeli streamlining provider Run:ai cleared a key regulatory hurdle with EU approval without conditions. |
Illumina, Inc. (ILMN) Sees Modest Gains Amid Regulatory Approvals and Market SpeculationWe recently published a list of 14 Stocks That Jim Cramer Recently Talked About. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other stocks that Jim Cramer recently talked about. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer continued to talk about […] |
Video: Asking Our Employees Why They Choose IlluminaNORTHAMPTON, MA / ACCESSWIRE / December 18, 2024 / Illumina How would it feel to know the work you do each day is impacting human health on a global scale? As genomics enables a new era of heath care, Illumina technology is empowering personalized ... |
Is There Now An Opportunity In Illumina, Inc. (NASDAQ:ILMN)?Today we're going to take a look at the well-established Illumina, Inc. ( NASDAQ:ILMN ). The company's stock saw a... |
What's Going On With Illumina Stock On Monday?On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:GRAL). Also |